INSUBCONTINENT EXCLUSIVE:
Good morning!
The domestic stock market on Thursday showed early signs of a possible breakout from its consolidation range
(DRL) with a target price of Rs 2,580 after Prasco announced the authorised generic launch of Nuvaring
The drug is one of the key expected launches for DRL in FY21, but launches by competitors earlier than the company could affect the product
price of Rs 100 after the bank disclosed its divergence details on asset quality and provisioning for FY19
The remaining provisioning divergence at Rs 2,600 crore amounts to 2.7 per cent of FY20 book value (post tax basis) and around 55 per cent
of FY20 PBT, said Morgan Stanley
(India) with a target price of Rs 5,822
size give it an edge, said Anand Rathi
The brokerage has modelled 24 per cent and 32 per cent CAGRs over FY20-22 in revenue and PAT, respectively, resulting in the RoCE expanding
from 26 per cent in FY19 to around 36 per cent in FY21 and FY22
Industries with a target price of Rs 700
brand image and strong distribution network in rural market, said Haitong
While Ebitda is projected to remain relatively stable over FY19-FY22, the quality of profit could improve on rising contribution from
product business, it said
The management clearly stated its intention not to infuse further capital in Idea, said HSBC
The management believes the issues marring the telecom sector are too big to be solved by further capital infusion, it said
Rising contribution from Novelis and potential merger with Aleris, which is not in the base case, make Hindalco a compelling investment
Shares of Hindalco Industries ended down 0.1 per cent at Rs 213.50 on Wednesday.